Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2011

01-07-2011 | Letter to the Editor

Acute megakaryoblastic leukemia AML FAB-M7 in a patient 15 years after kidney transplantation

Authors: Alexandra Scholze, Igor W. Blau, Martin Tepel

Published in: Annals of Hematology | Issue 7/2011

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Cohen D, Galbraith C (2003) General health management and long-term care of the renal transplant recipient. Am J Kidney Dis 38(Suppl 6):S10–S24
2.
Gorschlüter M, Glasmacher A, Risse F, Klein B, Klehr HU, Mezger J (1997) Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. Nephrol Dial Transplant 12:593–595PubMedCrossRef
3.
Subar M, Gucalp R, Benstein J, Williams G, Wiernik PH (1996) Acute leukaemia following renal transplantation. Med Oncol 13:9–13PubMedCrossRef
4.
Thalhammer-Scherrer R, Wieselthaler G, Knoebl P, Schwarzinger I, Simonitsch I, Mitterbauer G, Berlakovich GA, Mannhalter C, Haas OA, Mayer G, Muehlbacher F, Wolner E, Klepetko W, Lechner K, Jaeger U (1999) Post-transplant acute myeloid leukemia (PT-AML). Leukemia 13:321–326PubMedCrossRef
Metadata
Title
Acute megakaryoblastic leukemia AML FAB-M7 in a patient 15 years after kidney transplantation
Authors
Alexandra Scholze
Igor W. Blau
Martin Tepel
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2011
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-010-1084-0

Other articles of this Issue 7/2011

Annals of Hematology 7/2011 Go to the issue

Original Article

Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells

Original Article

Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells

Original Article

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

Original Article

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP

Erratum

Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

Letter to the Editor

Autoimmune hemolytic anemia and autoimmune neutropenia in a child with erythroblastopenia of childhood (TEC) caused by human herpesvirus-6 (HHV-6)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits